iCAD, Inc.
4 Townsend West
Suite 17
Nashua
New Hampshire
03063
United States
Tel: 603-882-5200
Fax: 603-880-3843
Website: http://www.icadmed.com/
335 articles about iCAD, Inc.
-
iCAD to Participate at the Imagine AI + Healthcare Investor Summit
12/6/2021
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, President and incoming Chief Executive Officer, will present a corporate overview at Oppenheimer’s Imagine AI + Healthcare Investor Summit being hosted by Oppenheimer in partnership with the Alliance for AI in Healthcare (AAIH).
-
iCAD Announces Compelling New and Real-World Data Demonstrating the Value of ProFound AI to be Presented at RSNA 2021
11/29/2021
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new and real-world research demonstrating the value of ProFound AI® for Digital Breast Tomosynthesis (DBT) will be highlighted at the 107th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA).
-
iCAD to Participate in the 12th Annual Craig-Hallum Alpha Select Conference
11/11/2021
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it will participate in the 12th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 16, 2021, starting at 9:00 AM ET.
-
iCAD Reports Financial Results for the Quarter Ended September 30, 2021
11/9/2021
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, reported its financial and operating results for the three and nine months ended September 30, 2021.
-
There were a fair number of clinical trial announcements last week. Here’s a look.
-
iCAD’s Xoft Brain IORT Demonstrates Significant Improvement in Overall Survival in Recurrent Glioblastoma According to Comparative Study
8/31/2021
iCAD, Inc. today announced that encouraging results from a prospective two center comparative study evaluating the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of recurrent glioblastoma (GBM)
-
iCAD’s ProFound AI for Digital Breast Tomosynthesis Version 3.0 Receives CE Mark Approval
6/14/2021
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that ProFound AI® Version 3.0 for Digital Breast Tomosynthesis received CE Mark approval.
-
iCAD Signs Global Distribution Agreement with Sectra
6/8/2021
Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwide
-
iCAD Announces Educational Webinar Featuring Leading Global Experts Discussing New Multidisciplinary Approach for Treating Brain Tumors, May 25
5/17/2021
Company sees positive momentum as research contributes to growing body of evidence supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer
-
iCAD Reports Financial Results for First Quarter Ended March 31, 2021
4/28/2021
First Quarter Revenues of $8.6 Million Represented 32% Year-Over-Year Growth Driven by 28% Growth in Detection Revenue and 41% Growth in Therapy Revenue
-
iCAD to Report First Quarter 2021 Financial Results on Wednesday, April 28
4/20/2021
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, April 28. Wednesday April 28th @ 4:30pm ET
-
New Research Confirms iCAD’s ProFound AI Aids Breast Cancer Detection with Digital Breast Tomosynthesis, Improves Radiologists’ Workflow
4/19/2021
Studies presented at two leading breast imaging conferences demonstrate ProFound AI helps radiologists identify normal mammograms and those with increased likelihood of malignancy with precision
-
iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition
4/5/2021
Company expects preliminary estimated revenues to exceed $8.1 million Successor CFO search underway
-
New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates
3/31/2021
Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48% of interval cancers and 93% of subgroups that include false-negatives and minimal sign lesions
-
iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography
3/15/2021
Company’s third generation AI solution offers significant improvement in algorithm specificity performance and faster processing compared to previous versions of the software Deep learning technology builds upon iCAD’s established leadership in mammography AI
-
iCAD Announces Pricing of $22.0 Million Public Offering of Common Stock - Mar 03, 2021
3/3/2021
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced the pricing of an underwritten public offering of 1,222,222 shares of its common stock at a public offering price of $18.00 per share.
-
iCAD Announces Proposed Public Offering of Common Stock - Mar 02, 2021
3/2/2021
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
-
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2020
2/24/2021
Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI® Product Revenue
-
iCAD to Report Fourth Quarter 2020 Financial Results on Wednesday, February 24
2/18/2021
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that it will release financial results for the fourth quarter and year ended December 31, 2020, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, February 24.
-
iCAD to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2/16/2021
iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18 th at 4:30pm ET